Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $524.65 | 8 | 96.8% |
| Gift | $17.24 | 1 | 3.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $154.02 | 3 | $0 (2019) |
| Regeneron Pharmaceuticals, Inc. | $131.36 | 1 | $0 (2022) |
| Astellas Pharma US Inc | $117.61 | 1 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $86.31 | 1 | $0 (2019) |
| Allergan Inc. | $19.29 | 1 | $0 (2017) |
| Carl Zeiss Meditec, Inc. | $17.24 | 1 | $0 (2020) |
| ViiV Healthcare Company | $16.06 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $117.61 | 1 | Astellas Pharma US Inc ($117.61) |
| 2023 | $16.06 | 1 | ViiV Healthcare Company ($16.06) |
| 2022 | $131.36 | 1 | Regeneron Pharmaceuticals, Inc. ($131.36) |
| 2020 | $17.24 | 1 | Carl Zeiss Meditec, Inc. ($17.24) |
| 2019 | $240.33 | 4 | Genentech USA, Inc. ($154.02) |
| 2017 | $19.29 | 1 | Allergan Inc. ($19.29) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/31/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $117.61 | General |
| Category: Ophthalmology | ||||||
| 02/21/2023 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $16.06 | General |
| Category: HIV | ||||||
| 09/21/2022 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $131.36 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/13/2020 | Carl Zeiss Meditec, Inc. | None Specified (Medical Supply) | Gift | In-kind items and services | $17.24 | General |
| 06/10/2019 | Novartis Pharmaceuticals Corporation | DUREZOL (Drug) | Food and Beverage | In-kind items and services | $86.31 | General |
| Category: OPHTHALMOLOGY | ||||||
| 04/04/2019 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $20.05 | General |
| Category: Ophthalmology | ||||||
| 04/04/2019 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $14.17 | General |
| Category: Ophthalmology | ||||||
| 02/10/2019 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $119.80 | General |
| Category: Ophthalmology | ||||||
| 03/21/2017 | Allergan Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $19.29 | General |
| Category: RETINA | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 2,197 | 8,027 | $6.6M | $1.6M |
| 2022 | 12 | 2,774 | 11,128 | $5.9M | $2.2M |
| 2021 | 12 | 2,665 | 10,793 | $4.2M | $2.0M |
| 2020 | 14 | 2,936 | 11,023 | $4.1M | $2.0M |
All Medicare Procedures & Services
51 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 136 | 1,164 | $2.8M | $806,226 | 28.9% |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 2023 | 77 | 1,601 | $1.7M | $348,698 | 20.0% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 76 | 710 | $525,400 | $131,551 | 25.0% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 609 | 1,190 | $404,600 | $107,235 | 26.5% |
| 67028 | Injection of drug into eye | Office | 2023 | 233 | 985 | $793,210 | $94,850 | 12.0% |
| 92134 | Imaging of retina | Office | 2023 | 632 | 1,598 | $175,780 | $47,496 | 27.0% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 173 | 487 | $116,880 | $31,620 | 27.1% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 144 | 157 | $23,550 | $2,834 | 12.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $11,500 | $2,256 | 19.6% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 16 | 16 | $6,400 | $1,684 | 26.3% |
| 92250 | Photography of the retina | Office | 2023 | 47 | 54 | $6,468 | $1,577 | 24.4% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 11 | 22 | $8,800 | $1,466 | 16.7% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 20 | 20 | $8,000 | $1,408 | 17.6% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 137 | 1,258 | $2.1M | $905,867 | 42.7% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 141 | 3,871 | $2.2M | $866,110 | 38.6% |
| 67028 | Injection of drug into eye | Office | 2022 | 286 | 1,324 | $751,820 | $128,555 | 17.1% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 639 | 1,009 | $285,660 | $90,850 | 31.8% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 308 | 1,006 | $203,700 | $69,883 | 34.3% |
| 92134 | Imaging of retina | Office | 2022 | 782 | 2,090 | $191,140 | $64,331 | 33.7% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 125 | 125 | $40,500 | $13,773 | 34.0% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2022 | 228 | 270 | $22,200 | $5,150 | 23.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 38 | 38 | $15,250 | $4,235 | 27.8% |
| J7999 | Compounded drug, not otherwise classified | Office | 2022 | 17 | 54 | $21,600 | $3,568 | 16.5% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 23 | 26 | $8,000 | $2,633 | 32.9% |
| 92250 | Photography of the retina | Office | 2022 | 50 | 57 | $6,270 | $1,693 | 27.0% |
About Dr. William Thompson, MD
Dr. William Thompson, MD is a Ophthalmology healthcare provider based in Ft Lauderdale, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1396743480.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Thompson, MD has received a total of $541.89 in payments from pharmaceutical and medical device companies, with $117.61 received in 2024. These payments were reported across 9 transactions from 7 companies. The most common payment nature is "Food and Beverage" ($524.65).
As a Medicare-enrolled provider, Thompson has provided services to 10,572 Medicare beneficiaries, totaling 40,971 services with total Medicare billing of $7.8M. Data is available for 4 years (2020–2023), covering 51 distinct procedure/service records.
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist
- Location Ft Lauderdale, FL
- Active Since 07/12/2005
- Last Updated 07/14/2021
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1396743480
Products in Payments
- Lucentis (Biological) $154.02
- EYLEA (Biological) $131.36
- Izervay (Drug) $117.61
- DUREZOL (Drug) $86.31
- OZURDEX (Drug) $19.29
- None Specified (Medical Supply) $17.24
- CABENUVA (Biological) $16.06
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Ft Lauderdale
Sunir Joshi, M.d, M.D
Ophthalmology — Payments: $924,809
Dr. Eduardo Uchiyama, M.d, M.D
Ophthalmology — Payments: $361,047
Dr. Robert Kramm, Md, Mse, MD, MSE
Ophthalmology — Payments: $128,093
Dr. Mario Del Cid, Md, MD
Ophthalmology — Payments: $14,565
Barry Taney, Md, MD
Ophthalmology — Payments: $11,060
Lawrence Halperin, Md, MD
Ophthalmology — Payments: $10,765